Related Experiment Video
Updated: Aug 19, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
Outpatient management of heart failure
1Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, 1111 West 10 Street, Indianapolis, IN 46202, USA.
Insights
Newer heart failure therapies improve survival and function, expanding beyond traditional hemodynamic treatments. Expanding "triple" therapy to "quadruple" therapy with carvedilol is recommended for better outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Outpatient heart failure management involves hemodynamic and disease-modifying therapies.
- Traditional therapies focus on improving hemodynamics, while newer agents enhance survival and function.
Observation:
- Hemodynamic "triple" therapy includes digoxin, antihypertensives, and diuretics.
- Disease-modifying therapy incorporates agents like ACE inhibitors, ARBs, spironolactone, hydralazine/nitrates, and beta-blockers.
Findings:
- Carvedilol, a beta-adrenergic blocker, is a key component of disease-modifying therapy.
- The efficacy of newer therapies supports an expanded treatment regimen.
Implications:
- The standard "triple" therapy for heart failure should evolve to "quadruple" therapy.
- Incorporating carvedilol into heart failure treatment offers improved survival and function.
Abstract:
The outpatient treatment of heart failure can be divided into 2 broad categories: older therapies, which improve hemodynamics, and newer therapies, which increase survival and improve function. Hemodynamic "triple" therapy includes digoxin to increase cardiac inotropy, antihypertensives to lower systolic pressure, and diuretics to remove fluid and decrease filling pressures. Disease-modifying therapy requires the use of specific agents to lower blood pressure (angiotensin-converting enzyme inhibitors, angiotensin II blockers, spironolactone, or hydralazine and nitrates) and beta-adrenergic blockade with carvedilol. The success of these newer therapies suggests that the standard triple therapy for heart failure should be expanded to "quadruple" therapy that includes carvedilol.
More Related Videos
Related Concept Videos
Mitral Regurgitation IV: Nursing Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy VI: Nursing Management

